Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating total tumor load (TTL) to predict metastasis in four or more axillary lymph nodes in HR +/HER2- breast cancer patients: the TULIP4N + study.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.

NPJ breast cancer·2026
Same author

Taste alterations in breast cancer patients undergoing chemotherapy: an observational study.

Frontiers in nutrition·2026
Same author

World Health Organization classification of tumours of the breast 6th edition 2026.

Histopathology·2026
Same author

Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease.

Biomarker research·2026
Same author

Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies.

Leukemia·2026
Same journal

Impact of WHO Classification of Tumours on cancer prevention, diagnosis, research, public health, and economics.

Journal of the National Cancer Institute. Monographs·2026
Same journal

Cancer epigenetics: unraveling etiology and mechanisms to advance prevention.

Journal of the National Cancer Institute. Monographs·2026
Same journal

Oncogenic infections: targets highly amenable to cancer prevention.

Journal of the National Cancer Institute. Monographs·2026
Same journal

The continuing importance of the IARC's international remit in cancer research.

Journal of the National Cancer Institute. Monographs·2026
Same journal

Environmental and occupational cancer: highlighting research contributions from the IARC on its 60th anniversary.

Journal of the National Cancer Institute. Monographs·2026
Same journal

Progress in identifying the preventable causes of human cancer: the experience of the IARC Monographs program.

Journal of the National Cancer Institute. Monographs·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

The pathologic complete response open question in primary therapy.

Caterina Marchiò1, Anna Sapino

  • 1Department of Biomedical Sciences and Human Oncology, University of Turin, Turin 10126, Italy.

Journal of the National Cancer Institute. Monographs
|November 2, 2011
PubMed
Summary
This summary is machine-generated.

Accurate pathological diagnosis before neoadjuvant therapy and specimen examination after treatment are crucial for breast cancer management. Pathological complete response is a key predictor of patient outcomes, while residual tumor cells do not significantly impact prognosis.

Related Experiment Videos

Last Updated: May 28, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Oncology
  • Pathology
  • Breast Cancer Research

Background:

  • Neoadjuvant treatment for breast cancer requires precise pathological diagnosis before therapy and thorough examination of post-treatment specimens.
  • Assessing intratumor heterogeneity through core biopsies and lymph node cytology aids in treatment planning.

Purpose of the Study:

  • To highlight the importance of pre-treatment pathological diagnosis and post-treatment specimen evaluation in neoadjuvant-treated breast cancer.
  • To emphasize the prognostic significance of pathological complete response.

Main Methods:

  • Utilizing multiple core biopsies for assessing tumor heterogeneity.
  • Employing fine needle aspiration cytology for suspicious lymph nodes.
  • Detailed pathological examination of surgical specimens post-neoadjuvant therapy.

Main Results:

  • Pathological complete response, defined as no residual invasive tumor, is an independent predictor of favorable outcomes.
  • Clinical response may not always align with pathological response.
  • Residual isolated tumor cells in the primary tumor or lymph nodes do not adversely affect patient prognosis.

Conclusions:

  • Accurate pre-treatment pathological assessment and post-treatment evaluation are essential in managing neoadjuvant-treated breast cancer.
  • Pathological complete response is a critical endpoint for predicting patient outcomes.
  • The presence of isolated tumor cells does not appear to impact long-term prognosis.